CKPT - Checkpoint Therapeutics Inc
IEX Last Trade
2.35
0.010 0.426%
Share volume: 155,233
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$2.34
0.01
0.43%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
| Report Date | 2022-05-12 | 2022-08-12 | 2022-11-10 | 2023-03-31 | 2023-05-15 | 2023-08-14 | 2023-11-13 | 2024-03-22 | |
| Assets | |||||||||
| Total Assets | 42.906 M | 32.083 M | 21.620 M | 13.290 M | 5.896 M | 8.338 M | 2.218 M | 5.378 M | |
| Current Assets | 42.906 M | 32.083 M | 21.620 M | 13.290 M | 5.896 M | 8.338 M | 2.218 M | 5.378 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 1.378 M | 1.178 M | 1.094 M | 1.149 M | 1.015 M | 886.000 K | 415.000 K | 450.000 K | |
| Short Term Investments | 1.378 M | 1.178 M | 1.094 M | 1.149 M | 1.015 M | 886.000 K | 415.000 K | 450.000 K | |
| Total Receivables | 52.000 K | 18.000 K | 48.000 K | 73.000 K | 35.000 K | 31.000 K | 31.000 K | 0.000 | |
| Current Cash | 41.476 M | 30.887 M | 20.478 M | 12.068 M | 4.846 M | 7.421 M | 1.772 M | 4.928 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 42.906 M | 32.083 M | 21.620 M | 13.290 M | 5.896 M | 8.338 M | 2.218 M | 5.378 M | |
| Total liabilities | 22.690 M | 24.621 M | 22.955 M | 32.773 M | 28.075 M | 31.608 M | 21.261 M | 18.425 M | |
| Total current liabilities | 22.690 M | 24.621 M | 22.955 M | 32.773 M | 28.075 M | 31.608 M | 21.261 M | 18.425 M | |
| Accounts Payable | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 20.216 M | 7.462 M | -1.335 M | -19.483 M | -22.179 M | -23.270 M | -19.043 M | -13.047 M | |
| Common stock | 8.505 M | 8.751 M | 8.857 M | 9.229 M | 11.749 M | 15.700 M | 19.988 M | 27.532 M | |
| Retained earnings | -216.710 M | -230.852 M | -241.464 M | -262.486 M | -272.960 M | -289.481 M | -295.205 M | -314.333 M |